Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$25.39 USD
-0.93 (-3.53%)
Updated Oct 13, 2025 04:00 PM ET
After-Market: $25.45 +0.06 (0.24%) 6:52 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Beam Therapeutics Inc. has a PEG ratio of 7.79 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.09.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BEAM 25.39 -0.93(-3.53%)
Will BEAM be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
Other News for BEAM
Slingshot Bullish appears for BEAM after 5.56% move
Pocket Pivot appears for BEAM after 3.22% move
HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target | BEAM Stock News
H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Beam Therapeutics initiated with a Buy at Jefferies